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“Science never solves a problem without creating ten more.”
George Bernard Shaw
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INTRODUcTION
During my first years in Medical School, while studying embryology, I was amazed the prevalence of 
congenital anomalies was not higher than the current 3-5% taking into account the complexity of the 
development process of the human embryo. Being part of a generation growing up with children my 
own age who had phocomelia, I was aware that things could go wrong during human development. 
The reason for most cases of phocomelia in my generation was Softenon (thalidomide), marketed as 
the ‘little white sleeping pill’ promoting that it could be safely used by expecting mothers. 
Although the thalidomide disaster occurred fifty years ago and was reason to establish drug regulatory 
authorities in many countries including the Netherlands, safety of drug exposure during pregnancy 
was not high on the agenda of the authorities or a subject of pharmacovigilance until recently. The 
European authorities, however, had acknowledged this lack and the ‘Guideline on the exposure to 
medicinal products during pregnancy: need for post-authorisation data’ did come into effect on May 
2006. A systematic way to monitor drug safety in pregnancy is not established, but the International 
Society for Pharmacoepidemiology (ISPE) has started a special interest group (SIG) on medicines in 
pregnancy to discuss this issue.
Teratogenicity of drugs for human use is unknown at the moment of marketing authorisation of new 
chemical entities. Although, animal data on potential teratogenicity or developmental disorders is 
limited and will be extrapolated for human risk assessment, the risk in animals might not provide 
the accurate prediction in humans [1]. Drugs not showing teratogenicity in animal studies might be 
teratogenic in humans, as was for instance the case for thalidomide [2]. Women of childbearing 
potential and especially pregnant women are excluded in clinical trials, but if necessary will receive 
the drug after registration. Pregnant women needing treatment with drugs might get these after 
careful weighing benefits and risks at individual basis. 
With the introduction of the Risk Management Plans (RMPs) regulatory authorities are aiming at early 
detection and minimisation of drug related risks, possible teratogenic risk of drugs has become 
more prominent. Pregnancy exposure is a standard topic in RMPs, and often included as missing 
information. Because of this missing information pregnancy registries are more and more introduced 
as additional risk minimisation measure to cover this issue. Pregnancy exposure was already a 
continuous topic in periodic safety update reports, but has become more emphasized during the 
last years.
background
A teratogen is defined as a substance which has a harmful effect on the embryo and/or foetus 
causing structural defects, known as congenital anomalies, but also functional defects, spontaneous 
abortions / foetal death and transplacental carcinogenesis. Other adverse effects can be infertility of 
the want-to-be-parent, intra-uterine growth retardation or pharmacological effects such as withdrawal 
reactions. Exposure to a teratogenic agent during pregnancy will not always result in adverse foetal 
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effects. Factors influencing teratogenic outcomes include dose, duration, gestational age, concurrent 
exposures and the biological and genetic susceptibility of the mother and embryo or foetus. In most 
cases it takes a substantial amount of time to generate sufficient data to conclude that a drug is a 
human teratogen, but also to proof that it is not teratogenic. Because drugs with teratogenicity in 
animals are not recommended for women of childbearing potential, and in case treatment with these 
drugs is necessary these women will be advised to use contraceptive methods [3], for instance 
leflunomide. Examples with proven teratogenicity are among others isotretinoin [4], thalidomide [4] 
and anti-epileptic drugs. For certain anti-epileptic drugs it took some decades before its teratogenicity 
could be determined [6,7]. Reasons to get reliable data about the possible teratogenic effects of 
drugs in humans are the outcome (teratogenic effect) is rare, the use of a specific drug in pregnant 
women is rare and specific congenital anomalies will be investigated to identify a relation instead of 
all congenital anomalies together.
The prevalence of infants born with major congenital anomalies is approximately 3% [8]. A Dutch 
study showed a prevalence of 2% in Amsterdam [9]. Approximately 1.5% of the congenital anomalies 
are caused by maternal drug use in the first trimester of pregnancy [10]. According to a study from 
the USA [11] 1.1% pregnancies is exposed to teratogenic drugs. This thesis focuses on congenital 
anomalies due to parental drug use, but we should bear in mind that also other products used in daily 
life such as solvents or plasticisers (phthalates) [12] can cause congenital anomalies.
To assess the risk of congenital anomalies the following elements of drug exposure during pregnancy 
should be present: dose, timing of exposure, abnormality, maternal disease and drug characteristics. 
Most drugs have a time ‘window’ of the highest risk of the congenital anomaly. For instance, for 
thalidomide the highest risk for congenital anomalies is exposure between day 35 and 49 after last 
menstrual period [13]. For isotretinoin, the first critical period of exposure is the 2nd to the 5th weeks 
after conception causing a high rate (40%) of spontaneous abortion and the second period of up 
to 10 weeks causing 26% risk of congenital anomalies [3,14]. In addition, exposure of isotretinoin 
beyond the first trimester is associated with developmental delays [14,15].
Post-marketing studies
In post-marketing setting, two main study approaches seem most appropriate to identify teratogens: 
follow-up or cohort studies and case-control surveillance studies [16]. Another approach is small 
cohort studies with physical examination for minor anomalies [17], because minor anomalies in an 
infant might be part of a specific pattern of congenital anomalies and might be an indication for a not 
yet diagnosed major congenital anomaly. In the past, case-crossover and case-time-control design 
were tested in congenital anomaly epidemiology, but these designs did not offer clear advantages 
over the case-control design [18]. It was concluded that the major strength of case-control studies is 
the statistical power permitting efficient identification of teratogens. In addition, criteria for establishing 
human teratogenicity state that there should be ‘consistent findings by two or more epidemiologic 
studies of high quality’ [19].
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Safety issues
During recent years, regularly safety issues concerning adverse reactions of congenital anomalies 
with drug exposure during pregnancy are discussed. Issues discussed on pregnancy exposures 
were for instance: isotretinoin, Selective Serotonin Receptor Inhibitors (SSRIs) [20], lamotrigine [21], 
Tumour Necrosis Factor-alpha (TNF-α) antagonists [22] and fertility issues due to chronic Non-
steroidal Anti-inflammatory Drug (NSAID) use [23]. 
Even less known than maternal drug exposure and the effect on the embryo are the effects of paternal 
drug use periconception and during pregnancy on the embryo or foetus. Paternal drug is a topic very 
rarely investigated. However, paternal use of finasteride might have possible teratogenic effects, such 
as hypospadia, or the adverse effect of paroxetine on semen that may cause decreased fertility [24].
Risk minimisation measures – Pregnancy Prevention Plan (PPP)
Based on the harmonised tripartite guideline on pharmacovigilance planning of the International 
conference on harmonisation (ICH) [25], the EU and the Food and Drug Administration (FDA) in the 
USA have implemented procedures for new chemical entities or products on submission of a Risk 
Management Plan (RMP) [26] or Risk Evaluation and Mitigation Strategies (REMS) [27], respectively. 
The RMP might include risk minimisation measures based on the safety concerns. Risk minimisation 
measures, such as a PPP, will have to be evaluated during the life-cycle of the drug as one of the 
aspects of the continuous benefit-risk evaluation of a drug. 
Drugs with mild to moderate human teratogenic risk are contraindicated in pregnant women and not 
recommended for women with a child wish and are requested to implement risk minimisation measures 
for intra-uterine exposure. For all drugs, but especially for these drugs, individual weighing of benefits 
and risks will have to take place before prescribing these drugs for women with a child wish, because 
stopping of the drug during pregnancy might also be harmful. Drugs with a high teratogenic risk, such 
as thalidomide or isotretinoin are contraindicated in pregnant women and women of childbearing 
potential. Women of childbearing potential might receive these drugs only under special circumstances 
stated in the Summary of Product Characteristics (SmPC) and specific risk minimisation measures, 
such as a PPP. A PPP will be implemented to minimise the risk on congenital anomalies due to intra-
uterine exposure to highly teratogenic drugs by pregnancy prevention.
In the European Union (EU), seven drugs have a PPP: thalidomide, lenalidomide; vitamin A derivatives 
acitretin, isotretinoin and alitretinoin; and endothelin receptor antagonists (ERAs) bosentan and 
ambrisentan. The latter two, have a teratogenic risk in animals but the relevance for humans is 
unknown. Elements in PPPs are among others a contra-indication for pregnancy, pregnancy tests 
before, during and after drug use, at least one method of contraception, educational material for 
physicians, pharmacists and patients, restricted supply of the drug for 30 days, prescription validity 
of 7 days, informed consent forms for patients to be signed, patient card/diary, and pregnanc Atrial 
Septal Defect y registry. Comparison of these PPPs and identification of common elements might 
result in recommendations to enhance uniformity and harmonisation of PPPs.
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Taking the isotretinoin PPP as an example; differences in the PPP between the various isotretinoin 
containing products for oral use started a harmonisation procedure for all isotretinoin containing 
products was approved by the European Commission in October 2003. However, in Europe, 
isotretinoin exposure during pregnancy still occurs as well as in the US despite the even stricter PPP, 
named iPLEDGE [28] which is regarded as a major concern. 
OUTlINE ThESIS
The objective of this thesis is to evaluate safety signals and concerns to drug exposure during 
pregnancy. In particular the pregnancy prevention programme of isotretinoin, a risk minimisation 
measure, will be evaluated. Based on these evaluations, recommendations will be made to improve 
and harmonise PPPs and to increase embedding of teratology in pharmacovigilance.
Part I of the thesis describes pregnancy prevention programmes (PPPs) in general and the drugs 
which have such a programme. The elements of a PPP are discussed in view of the characteristics 
of these specific drugs.
In Part II, one of the drugs with a PPP, isotretinoin is highlighted. This part consists of two chapters. 
The first chapter describes the situation in Europe, mainly following the regulatory referral on this 
drug and the design of an EU PPP. The situation in Europe is listed by a systemic literature review 
of studies including case reports performed in Europe and by a survey to all EU member states and 
Norway and Iceland on the implementation of this EU PPP. 
The second chapter of this part II deals with the situation in the Netherlands. First the adherence 
to the isotretinoin PPP by health care professionals (HCPs) is studied through online surveys with 
pharmacists and dermatologists. Secondly, several aspects of contraceptive use in women of 
childbearing potential using isotretinoin is studied by a drug utilisation study using a prescription 
database IADB.nl. Furthermore, pregnancies occurred during isotretinoin use in the Netherlands is 
studied in a survey among HCPs who had contacted TIS on this matter. Reasons for pregnancies 
and the failure of the PPP were evaluated.
Part III of this thesis consists of other signals discussed during the last years: paternal drug use of 
for instance finasteride and paroxetine, and tumour necrosis factor-alpha blockers and the VACTERL 
(vertebral defects, anal atresia, cardiac, tracheoesophageal, renal and limb abnormalities) association.
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•	 67% of the patients heard about the isotretinoin PPP from their treating physician.
•	 6% of the patients used isotretinoin for mild acne instead of moderate to severe acne.
•	 61% of the patients had a pregnancy test before starting isotretinoin treatment. 33% 
performs pregnancy tests on a monthly basis.
•	 11% of the pharmacists did ask for pregnancy test results.
•	 61% of the patients receives prescriptions covering one month treatment and 33% 
received prescriptions for three months.
•	 72% of responding patients uses contraceptive measures, the remaining patients were 
not sexually active. 17% did not use contraceptive measures with every sexual contact.
•	 50% of the patients considers the PPP a mutual responsibility of prescriber and patient.
 Results patient survey (n=18)
